<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737918</url>
  </required_header>
  <id_info>
    <org_study_id>URGE-II</org_study_id>
    <nct_id>NCT01737918</nct_id>
  </id_info>
  <brief_title>Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa</brief_title>
  <acronym>URGE-II</acronym>
  <official_title>Phase 1/2 Study of the Effect of TOT or Solifenacin After Cesa or Vasa on Urge Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universität Köln</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urge urinary incontinence can be a disorder caused by destroyed pelvic structures. We
      repaired the uteri-sacral ligaments (USL) by cesa or vasa. The study evaluates if solifenacin
      can lead to continence after surgery or if also the pubo-urethral ligaments (PUL) need to be
      repaired.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was hypothesized that urge urinary incontinence in women is based on the destruction of
      the uteri-sacral ligaments (USL)and the pubourethral ligaments (PUL). In a preliminary study
      (URGE I) we repaired the USL by cesa or vasa. Those patients who are still incontinent after
      cesa and vasa get the repair of the PUL by means of trans-obturator tapes (TOT). That
      treatment is compared to conservative medical treatment. Cross over after completion of three
      months is possible if no continence is achieved.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure of incontinence</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of urge symptoms</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Surgical Treatment of Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>trans obturatorial tape (TOT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placement of a sub-urethral tape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TOT</intervention_name>
    <arm_group_label>trans obturatorial tape (TOT)</arm_group_label>
    <other_name>trans obturatorial tape</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <arm_group_label>solifenacin</arm_group_label>
    <other_name>VESICUR 10mg per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prior vasa or cesa operation as part of the URGE I study

          -  stress urinary incontinence

          -  mixed urinary incontinence

        Exclusion Criteria:

          -  previous urogynecological surgery

          -  avulsion of cesa or vasa tape

          -  pregnancy

          -  neurologic/psychological reasons for incontinence

          -  body weight &gt;100kg

          -  syndrome of dry overactive bladder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfram H Jager, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Supervisor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfram H Jager, PhD</last_name>
    <phone>0049221478</phone>
    <phone_ext>4900</phone_ext>
    <email>wolfram.jaeger@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Mallmann, PhD</last_name>
    <phone>0049221478</phone>
    <phone_ext>4940</phone_ext>
    <email>peter.mallmann@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram H Jager, PhD</last_name>
      <phone>0049221478</phone>
      <phone_ext>4900</phone_ext>
      <email>wolfram.jaeger@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram H Jager, PhD</last_name>
      <phone>0049221478</phone>
      <phone_ext>4900</phone_ext>
      <email>wolfram.jaeger@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Mallmann, PhD</last_name>
      <phone>0049221478</phone>
      <phone_ext>4940</phone_ext>
      <email>peter.mallmann@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfram H Jager, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universität Köln</investigator_affiliation>
    <investigator_full_name>Professor Dr. Wolfram Jäger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>urge urinary incontinence, cesa, vasa, TOT, solifenacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

